Rockwell Medical reports Q3 2026 sales up 20%, cites pending Vantive dialysis unit deal
Rockwell Medical said the planned combination with Vantive's hemodialysis concentrates and machines business is projected to generate between $400 million and $450 million in annual revenue.
Rockwell Medical, Inc. reported third quarter 2026 results on November 12, 2026, disclosing that subsequent to the end of the third quarter it entered into an Equity and Asset Purchase Agreement with Vantive Limited, under which Rockwell Medical will acquire Vantive's hemodialysis concentrates, HD machines including AK-98, water treatment systems, and related consumables and technical services business.1 The deal also covers Vantive's one million square foot manufacturing campus in Medolla, Italy, which currently manufactures dry concentrate cartridges, HD machines, related parts and consumables, and water treatment systems supporting the broader HD product portfolio.1
The company said the combination with Vantive's global hemodialysis concentrates, hemodialysis machines, water treatment systems, and related consumables and technical services business is projected to generate annual revenue between $400 million and $450 million.1
On personnel, in July 2026 Rockwell Medical named Brian Cox as Vice President, Quality and Regulatory Compliance, with Cox bringing over 20 years of medical device experience spanning development, manufacturing, and regulatory compliance, including leadership roles at Abbott and Johnson & Johnson.1
For the quarter, net sales for the three months ended September 30, 2026 were $19.1 million, a 20% increase over $15.9 million for the same period in 2025,1 which the company attributed to greater purchasing from existing customers and additional sales to new customers in the western United States.1
On cash, cash, cash equivalents and investments available-for-sale at September 30, 2026 totaled $22.5 million, down from $24.8 million at June 30, 2026,1 which the company said was primarily driven by an increase in accounts receivable and prepaid expenses in the ordinary course of business, as well as capital purchases to further automate its manufacturing facilities.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.